Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)

NCT00663416 is registered in ClinicalTrials.gov with Stem Cell Therapeutics Corp. as lead sponsor.

NCT NCT00663416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00663416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)
Lead sponsor
Stem Cell Therapeutics Corp.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2008
Completion date
January 31, 2009
Enrollment
134 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

stroke